Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 6/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.32 |
| ▸ | CDK9 | P50750 | 8/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | UGCG | Q16739 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660626 | 0.93 | GABRG2 (0.37) | GABRG2GABRB3GABRA2DPP4NPC1 | |
| SCHEMBL2659113 | 0.92 | GABRG2 (0.47) | GABRG2GABRB3GABRA2DPP4 | |
| SCHEMBL2657622 | 0.91 | UGCG (0.35) | GABRG2GABRB3GABRA2DPP4UGCG | |
| SCHEMBL4916255 | 0.88 | GABRG2 (0.33) | GABRG2GABRB3GABRA2UGCGBACE1 | |
| SCHEMBL2658318 | 0.88 | GABRG2 (0.37) | GABRG2GABRB3GABRA2DPP4NPC1 | |
| SCHEMBL2657000 | 0.87 | GABRG2 (0.46) | GABRG2GABRB3GABRA2 | |
| SCHEMBL2658291 | 0.86 | CA1 (0.35) | GABRG2GABRB3GABRA2 | |
| SCHEMBL2655965 | 0.85 | GABRG2 (0.40) | GABRG2GABRB3GABRA2BACE1 | |
| SCHEMBL2657278 | 0.85 | GABRG2 (0.32) | GABRG2GABRB3GABRA2 | |
| SCHEMBL2655495 | 0.84 | GABRG2 (0.43) | GABRG2GABRB3GABRA2DPP4CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.